News

Harbour BioMed signs $350m anti-PD-L1 deal with Kelun-Biotech

Chinese companies Harbour BioMed and Sichuan Kelun-Biotech Biopharmaceutical have entered into an exclusive strategic collaboration for the development and commercialisation…